The impact of pharmacogenetics on HIV therapy.
The use of highly active antiretroviral therapy in the treatment of HIV infection has resulted in significant reductions in mortality and morbidity worldwide. However, there is considerable interindividual variability in patient outcomes in terms of drug disposition, drug efficacy and adverse events. The basis of these differences is multifactorial, but host genetics are believed to play a significant part. To date, most attempts to explain this variability have focused on isolated single nucleotide polymorphisms. The most exciting development to date is the discovery of human leukocyte antigen subtype B*5701 (HLA B*5701) as a strong predictor of the abacavir hypersensitivity reaction. There is a gradual move away from single candidate gene analyses towards a high throughput whole genome approach. These studies must be performed on well characterized cohorts and reported associations must be validated in independent, ethnically diverse populations.
Mahungu
T W
TW
Department of HIV Medicine, Royal Free NHS Trust, Pond Street, London NW3 2QG. wambura@gmail.com
Johnson
M A
MA
Owen
A
A
Back
D J
DJ
D023241:Antiretroviral Therapy, Highly Active; D023281:Genomics; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D010597:Pharmacogenetics; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors